Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
Launched by INSTITUT DU CANCER DE MONTPELLIER - VAL D'AURELLE · Jan 7, 2020
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The BCB CARCINOSE clinical trial is focused on creating a detailed database that collects important medical information about people with peritoneal carcinosis, a type of cancer that affects the lining of the abdomen. This study aims to gather both clinical and biological data to better understand this condition and improve future treatments. The trial is currently recruiting participants aged 18 and older who have been diagnosed with peritoneal carcinosis from digestive cancers or cancers of the peritoneum. Eligible participants should have received at least one surgical treatment, chemotherapy, or other therapies for their condition and must agree to provide biological and tissue samples for research.
Participants in this study can expect to undergo various assessments and provide samples as part of the research process. It’s essential that they understand the study's procedures and give their informed consent to join. Certain individuals may not be eligible, such as those without social protection, those who cannot understand the study requirements, or pregnant or breastfeeding women. Overall, this trial is an important step towards gathering crucial information that could lead to better care for patients with peritoneal carcinosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient over the age of 18;
- • Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer
- • Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease
- • Patient agree will all study procedure : biological samples \& tissues samples
- • Patient giving informed consent
- Exclusion Criteria:
- • Patient not affiliated to Social Protection system
- • Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
- • The level of French is insufficient to consent to the study and to response to the questionnaires
- • Patient under guardianship
- • Pregnancy ou breast-feeding women
- • Patient treated in case of an emergency
About Institut Du Cancer De Montpellier Val D'aurelle
The Institut du Cancer de Montpellier - Val d'Aurelle is a leading cancer research and treatment center located in Montpellier, France. Committed to advancing oncology through innovative clinical trials and research initiatives, the institute integrates cutting-edge scientific discovery with patient-centered care. With a multidisciplinary team of experts, it focuses on developing new therapeutic strategies and improving outcomes for cancer patients. The institute fosters collaboration with academic institutions and industry partners, aiming to translate research findings into effective clinical applications for a diverse range of cancers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Patients applied
Trial Officials
François QUENET,MD
Study Chair
Institut régional du cancer de Montpellier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials